Results 81 to 90 of about 19,663 (194)
Cancer Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background While immune checkpoint inhibitors (ICI) have transformed the landscape of clinical oncology, their application in rare malignancies such as anaplastic large cell lymphoma (ALCL) remains limited. Case We report a patient with relapsed/refractory (r/r) ALCL treated at the University Hospital Krems who achieved sustained complete ...
Constantin Klenner, Josef Singer
wiley +1 more source
, 2015 Liting Guo,1,* Haijun Zhang,1,* Weiwei Shao,2 Baoan Chen1 1Department of Hematology and Oncology (Key Department of Jiangsu Medicine), The Affiliated Zhongda Hospital, Medical School of Southeast University, Nanjing, 2Department of Pathology, the First ...
Guo L, Shao W, Zhang H, Chen B
core
BMC Cancer, 2018 Background To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to ...
Jianya Zhou +11 more
doaj +1 more source
Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma With SQSTM1::ALK Fusion
Diagnostic Cytopathology, Volume 54, Issue 9, Page E216-E220, September 2026.ABSTRACT Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare and aggressive variant of inflammatory myofibroblastic tumor (IMT) characterized by epithelioid morphology, atypical features, ALK rearrangements, and early metastatic potential.
Havva Gokce Terzioglu +2 more
wiley +1 more source
Clinical use of crizotinib for the treatment of non-small cell lung cancer
, 2013 Patrick J Roberts Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Absract: Discoveries over the last decade have fundamentally transformed the way we define lung cancer.
Roberts PJ
core
ALK Mutants Show Differential Response to Crizotinib
, 2011 Major finding: F1174L-mutated ALK shows reduced sensitivity to crizotinib inhibition. Mechanism: The F1174L mutation enhances the ATP-binding affinity of ALK.
core +1 more source
MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.The image illustrates how PROTACs utilize endocytosis, mediated by cell surface proteins, to overcome bioavailability limitations and enable efficient intracellular delivery. ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical ...
Huahua Chen +3 more
wiley +1 more source
Logistic considerations associated with exposure to Crizotinib.
, 2016 Logistic considerations associated with exposure to Crizotinib.
Vipul Doshi (3123906) +12 more
core +1 more source
MedComm, Volume 7, Issue 9, September 2026.In NSCLC patients with solitary distant metastasis (SDM), early local treatment significantly delays the progression to multi‐metastasis by 14 months (HR = 0.55) compared to delayed or no treatment. This multicenter cohort study highlights SDM as an indolent state, emphasizing the critical time window for effective local intervention. .
Kang Miao +10 more
wiley +1 more source
Translational Oncology, 2017 BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients.
Libo Zhang, Bing Wu, Sylvain Baruchel
doaj +1 more source